# Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane

**Authors:** Leonie F. Ott, Laura Keller, Nathan Bentley, Hümeyra Husseini‐Wüsthoff, René Werner, Marc Zinggeler, Jakoba Heidler, Parinaz Mossahebi Mohammadi, Cornelia Coith, Anne Pradines, Nikolas H. Stoecklein, Malte Löptien, Sven Peine, Maria Geffken, Corinna Güsmer, Mina Netkova‐Heintzen, Volkmar Müller, Elena Laakmann, Verena Thewes, Thomas M. Deutsch, Laura L. Michel, Andreas Schneeweiss, Andreas Trumpp, Jürgen Rühe, Thomas Brandtstetter, Sabine Riethdorf, Klaus Pantel

PMC · DOI: 10.1002/ijc.70216 · 2025-10-27

## TL;DR

A new filtration membrane rapidly enriches circulating tumor cells from large blood volumes, improving detection for breast cancer patients.

## Contribution

A functionalized nickel filtration membrane enables fast and efficient CTC enrichment from large blood volumes.

## Key findings

- The new filtration membrane detected CTCs in 95% of metastatic breast cancer patient samples.
- The system processed 40 mL of blood in 2.5 minutes with a filtration time of 40 seconds per 7.5 mL.
- The new system matched the FDA-approved CellSearch® in categorizing CTCs but with faster processing.

## Abstract

Circulating tumor cells (CTCs) are valuable liquid biopsy analytes as they facilitate an in‐depth characterization of disseminated tumors by a simple blood draw. Most CTC assays can only process limited blood volumes, potentially hampering the detection of cells of very low frequency, such as CTCs. Here, we introduce a novel, functionalized nickel filtration membrane, facilitating rapid enrichment of CTCs from various volumes of blood up to 40 mL and leukapheresis products. We validated this assay with different cancer cell lines and compared the performance of our new assay with that of the FDA‐cleared CellSearch® system. Performing a comparative analysis of 20 blood samples from patients with metastatic breast cancer, CTCs were found in 19/20 patients (95%), combining the results of both CTC enrichment assays. CTC counts/7.5 mL of blood ranged from 0 to 7280 (CTC filtration membrane) and 0 to 17,190 (CellSearch®). Applying the clinically relevant cut‐off of ≥5 CTCs/7.5 mL of blood, 19/20 samples processed with our CTC filter were categorized identically to those analyzed with the CellSearch® system. Furthermore, the filtration time of 40 s for 7.5 mL of blood represents an important advantage of our system, compared to other systems. Importantly, we also demonstrated the feasibility of processing blood samples of up to 40 mL or 2 × 108 nucleated blood cells in 2.5 min. Overall, our new system provides the advantage of performing ultra‐rapid enrichment of CTCs and upscaling the volume of blood that can be analyzed, which opens a new avenue for studies on CTC biology.

What's new?

Circulating tumor cells (CTCs) are promising prognostic biomarkers for cancer. CTCs are sometimes very sparse; however, they present technical challenges for their enrichment from whole blood. Here, the authors tested the CTC enrichment capacity of a new nickel‐based filtration membrane and compared its efficacy to that of an FDA‐approved system. Analyses show that the novel CTC filter categorized samples identically to the system of comparison, but with a shorter filtration time and a superior ability to process high‐volume samples. Thus, the novel nickel membrane offers fast CTC enrichment and is a promising option in cases of minimal residual disease.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), breast cancer (MESH:D001943)
- **Chemicals:** nickel (MESH:D009532)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12811197/full.md

---
Source: https://tomesphere.com/paper/PMC12811197